Neuren Pharmaceuticals Limited (ASX:NEU)
Australia · Delayed Price · Currency is AUD 20.48
+0.50 (2.50%)
Sep 5, 2025, 4:10 PM AEST
Neuren Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2016 - 2020 |
Operating Revenue | 217.19 | 213.24 | 231.93 | 14.55 | - | 0.72 | Upgrade |
Other Revenue | 1.67 | 3.59 | 0.02 | 0.86 | 3.2 | - | Upgrade |
| 218.86 | 216.83 | 231.94 | 15.42 | 3.2 | 0.72 | Upgrade | |
Revenue Growth (YoY) | 12.09% | -6.51% | 1404.46% | 382.23% | 345.89% | 44.85% | Upgrade |
Cost of Revenue | 29.98 | 32.97 | 26.75 | 12.71 | 9.52 | 7.76 | Upgrade |
Gross Profit | 188.88 | 183.86 | 205.19 | 2.71 | -6.32 | -7.05 | Upgrade |
Selling, General & Admin | 4.81 | 4.7 | 5.95 | 3.44 | 1.91 | 1.76 | Upgrade |
Operating Expenses | 4.81 | 4.7 | 5.95 | 3.44 | 1.91 | 1.76 | Upgrade |
Operating Income | 184.07 | 179.16 | 199.25 | -0.73 | -8.23 | -8.81 | Upgrade |
Interest & Investment Income | 11.47 | 11.01 | 5.69 | 0.39 | 0.04 | 0.15 | Upgrade |
Currency Exchange Gain (Loss) | -2.11 | -7.24 | 2.43 | 1.23 | 0.4 | -0.63 | Upgrade |
Other Non Operating Income (Expenses) | -2.62 | - | -2.23 | -0.7 | - | 0.1 | Upgrade |
EBT Excluding Unusual Items | 190.82 | 182.94 | 205.14 | 0.18 | -7.79 | -9.19 | Upgrade |
Pretax Income | 190.82 | 182.94 | 205.14 | 0.18 | -7.79 | -9.19 | Upgrade |
Income Tax Expense | 41.76 | 40.9 | 48.06 | - | - | - | Upgrade |
Earnings From Continuing Operations | 149.06 | 142.04 | 157.08 | 0.18 | -7.79 | -9.19 | Upgrade |
Net Income | 149.06 | 142.04 | 157.08 | 0.18 | -7.79 | -9.19 | Upgrade |
Net Income to Common | 149.06 | 142.04 | 157.08 | 0.18 | -7.79 | -9.19 | Upgrade |
Net Income Growth | 27.08% | -9.57% | 85270.11% | - | - | - | Upgrade |
Shares Outstanding (Basic) | 127 | 128 | 127 | 126 | 118 | 107 | Upgrade |
Shares Outstanding (Diluted) | 130 | 131 | 131 | 129 | 119 | 107 | Upgrade |
Shares Change (YoY) | -0.98% | 0.01% | 1.44% | 8.76% | 10.71% | 6.88% | Upgrade |
EPS (Basic) | 1.17 | 1.11 | 1.24 | 0.00 | -0.07 | -0.09 | Upgrade |
EPS (Diluted) | 1.15 | 1.09 | 1.20 | 0.00 | -0.07 | -0.09 | Upgrade |
EPS Growth | 28.33% | -9.58% | 120020.00% | - | - | - | Upgrade |
Free Cash Flow | 137.56 | -11.28 | 184.89 | 3.58 | -9.98 | -8.08 | Upgrade |
Free Cash Flow Per Share | 1.06 | -0.09 | 1.41 | 0.03 | -0.08 | -0.08 | Upgrade |
Gross Margin | 86.30% | 84.80% | 88.47% | 17.55% | -197.65% | - | Upgrade |
Operating Margin | 84.10% | 82.63% | 85.90% | -4.75% | -257.52% | -1228.59% | Upgrade |
Profit Margin | 68.11% | 65.51% | 67.72% | 1.19% | -243.79% | -1282.15% | Upgrade |
Free Cash Flow Margin | 62.85% | -5.20% | 79.71% | 23.22% | -312.17% | -1127.48% | Upgrade |
EBITDA | 184.1 | 179.18 | 199.26 | -0.72 | -8.23 | -8.8 | Upgrade |
EBITDA Margin | 84.11% | 82.64% | 85.91% | -4.68% | -257.27% | - | Upgrade |
D&A For EBITDA | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | Upgrade |
EBIT | 184.07 | 179.16 | 199.25 | -0.73 | -8.23 | -8.81 | Upgrade |
EBIT Margin | 84.10% | 82.63% | 85.90% | -4.75% | -257.52% | - | Upgrade |
Effective Tax Rate | 21.88% | 22.36% | 23.43% | - | - | - | Upgrade |
Revenue as Reported | 235.46 | 227.85 | 240.06 | 17.03 | 3.64 | 0.96 | Upgrade |
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.